These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 27536672)
21. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. Rojas-Rivera JE; Carriazo S; Ortiz A Clin Kidney J; 2019 Oct; 12(5):629-638. PubMed ID: 31583088 [TBL] [Abstract][Full Text] [Related]
22. [Expression of renal PLA2R in patients with idiopathic membranous nephropathy and its relationship with the curative effect of immunotherapy]. Wang LJ; Shang MH; Zhuge YF; Huang YX; Rong S; Tang ZH; Bao JF; Yu Q; Yuan WJ Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(1):4-8. PubMed ID: 26792599 [TBL] [Abstract][Full Text] [Related]
23. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy. Peng L; Wei SY; Li LT; He YX; Li B J Formos Med Assoc; 2016 Jan; 115(1):11-8. PubMed ID: 26315481 [TBL] [Abstract][Full Text] [Related]
24. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial. Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759 [TBL] [Abstract][Full Text] [Related]
25. Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial. Duan Y; Bai Y; Guo W; Wang L; Dai W; Guo W; Huang H; Liu W; Diao Z Nephrol Dial Transplant; 2023 Dec; 39(1):95-102. PubMed ID: 37437905 [TBL] [Abstract][Full Text] [Related]
26. New-Onset Diabetes Mellitus in Patients with Idiopathic Membranous Nephropathy Undergoing Tacrolimus and Low-Dose Corticosteroid Therapy. Shao L; Jin J; Ye B; Xu B; Li Y; Gong J; Zhang J; Chen M; He Q Kidney Blood Press Res; 2019; 44(6):1352-1362. PubMed ID: 31645044 [TBL] [Abstract][Full Text] [Related]
27. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases. Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027 [TBL] [Abstract][Full Text] [Related]
29. PLA2R and membranous nephropathy: A 3 year prospective Australian study. Hill PA; McRae JL; Dwyer KM Nephrology (Carlton); 2016 May; 21(5):397-403. PubMed ID: 26369693 [TBL] [Abstract][Full Text] [Related]
30. Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients. Liu Y; Li X; Ma C; Wang P; Liu J; Su H; Zhuo H; Kong X; Xu D; Xu D Clin Chim Acta; 2018 Jan; 476():9-14. PubMed ID: 29126817 [TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Schieppati A; Perna A; Zamora J; Giuliano GA; Braun N; Remuzzi G Cochrane Database Syst Rev; 2004 Oct; (4):CD004293. PubMed ID: 15495098 [TBL] [Abstract][Full Text] [Related]
32. Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. Chen Y; Schieppati A; Cai G; Chen X; Zamora J; Giuliano GA; Braun N; Perna A Clin J Am Soc Nephrol; 2013 May; 8(5):787-96. PubMed ID: 23449768 [TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis. Ren S; Wang Y; Xian L; Toyama T; Jardine M; Li G; Perkovic V; Hong D PLoS One; 2017; 12(9):e0184398. PubMed ID: 28898290 [TBL] [Abstract][Full Text] [Related]
34. Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis. Liu D; Yang Y; Kuang F; Qing S; Hu B; Yu X Int Immunopharmacol; 2019 May; 70():354-361. PubMed ID: 30852290 [TBL] [Abstract][Full Text] [Related]
35. Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy. Li P; Wei RB; Tang L; Wu J; Zhang XG; Chen XM Clin Nephrol; 2012 Dec; 78(6):456-64. PubMed ID: 23164414 [TBL] [Abstract][Full Text] [Related]
36. Membranous Nephropathy: Approaches to Treatment. Bomback AS; Fervenza FC Am J Nephrol; 2018; 47 Suppl 1():30-42. PubMed ID: 29852477 [TBL] [Abstract][Full Text] [Related]
39. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329 [TBL] [Abstract][Full Text] [Related]
40. [The relationship between anti-phospholipase A2 receptor antibody and idiopathic membranous nephropathy]. Lin W; Li H; Li X; Qin Y; Su Y; Yu Y; Guan Y; Duan L; Li Y; Wen Y; Li X Zhonghua Nei Ke Za Zhi; 2015 Sep; 54(9):783-8. PubMed ID: 26674797 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]